Sanofi US News

Data also Shows Men Consider Sexual Health to be an Important Priority

- In the MONARCH Study, Sarilumab Monotherapy Demonstrated Superiority Over Adalimumab Monotherapy in Adults with Active Rheumatoid Arthritis -

2016 could be the year of the last case of wild poliomyelitis worldwide

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

- Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress -

Funds will be used for phase II development and manufacturing

- Joshua Riff, M.D., Named Chief Executive Officer -

- Adlyxin™ is approved as Lyxumia® in more than 60 countries -

- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -

-- Findings reveal that some patients are frustrated and discontinued medication because they were not reaching their individualized A1C target quick enough --

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.

- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

- Collaborations Will Work towards Predicting Medication Adherence -

- Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities -

Pre-clinical immunogenicity and efficacy data published in Journal of Virology

Praluent is now covered by most health insurance and Medicare plans

- FDA decision anticipated in August 2016 -

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards

- Aims to advance animal health though internet-connected technology and networks -

Record-breaking holiday gift drive responds to increased homelessness rates

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- 74 percent of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal -

- Data Show Significant Improvement in Signs and Symptoms and Physical Function in Rheumatoid Arthritis Patients who were Inadequate Responders to or Intolerant of TNF-Alpha Inhibitors (TNF-IR) -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- Crucial vaccination with Raboral V-RG® continues to help protect wildlife and people against this fatal disease

New National Council on Aging Survey Shows Many Seniors Underestimate the Seriousness of the Flu, Largely Unaware of Vaccine Options1

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -

- Will work together on new digital technology and tools for diabetes -

- Praluent available early next week to U.S. patients -

- Leading influenza vaccine manufacturer to distribute more than 65 million doses to help protect people six months and older against the flu -

Sanofi and Regeneron Engage Academy Award® Winning Documentarian to Capture Behind-the-Scenes Look at Life with an Invisible Condition

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -

- Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway -

Despite CDC recommendations, fewer than 30% of teens received the second vaccination to help protect against meningococcal meningitis; new survey reveals potential reasons why

U.S. Patent and Trademark Office Honors Sanofi for its Anti-Malarial Treatment

Approval allows children to receive a combination of two recommended vaccinations

- Results support resubmission of U.S. New Drug Application in Q3 2015 -

Allergy sufferers are encouraged to share the #HappySmells they experience this season

- Robust and consistent LDL-C lowering demonstrated with Praluent™ in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date -

View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S.

America's Leading National Consumer Research Survey Ranks Gold Bond Products #1 in "U.S. Body Comfort and Relief" and "U.S. Skincare" Categories

Further education about hypoglycemia and routinely monitoring blood glucose levels is needed

- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -

Awards will provide funding for innovative diabetes researchers

Employees and contractors celebrate two decades of delivering essential items to Monroe County Head Start children and families

New program will spotlight America’s high cholesterol numbers

- The first and only four-strain influenza vaccine option administered intradermally -

Sanofi Commitment to Research and Develop TB Treatments, Diagnostics and Vaccines Spans More than 50 Years